What phantom share awards were granted to the BlackRock Health Sciences Trust (BME) insider?

The insider received 6,379.1521 phantom shares at a reference price of $41.87. Phantom shares are cash-settled units that mirror one share of common stock and vest in equal installments over three years, according to the compensation and vesting footnotes in the filing.

Portfolio manager at BlackRock Health Sciences (BME) exits 11,449 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BlackRock Health Sciences Trust portfolio manager Erin H. Xie reported a combination of phantom share awards and a stock sale. On January 30, 2026, 11,449.5087 shares of common stock were acquired through the exercise of derivative awards and then sold at $41.87 per share, leaving no directly held common stock.

Xie also received 6,379.1521 phantom shares, which are cash-settled units economically equivalent to common stock and vest in three annual installments, as described in prior and current phantom share grant footnotes.

Insider Trade Summary

11,449.509 shares exercised/converted

Mixed 6 txns

Insider Xie H Erin

Role Insider

Type	Security	Shares	Price	Value
Grant/Award	Phantom Shares	6,379.152	$41.87	$267K
Exercise	Phantom Shares	3,451.503	$0.00	--
Exercise	Phantom Shares	3,013.399	$0.00	--
Exercise	Phantom Shares	4,984.607	$0.00	--
Exercise	Common Stock	11,449.509	$0.00	--
Disposition	Common Stock	11,449.509	$41.87	$479K

Holdings After Transaction: Phantom Shares — 6,379.152 shares (Direct); Common Stock — 11,449.509 shares (Direct)

Footnotes (1)

A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. As previously reported on a Form 4 dated February 4, 2025, the Reporting Person was granted phantom shares on January 31, 2025 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. As previously reported on a Form 4 dated February 2, 2024, the Reporting Person was granted phantom shares on January 31, 2024 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. As previously reported on a Form 4 dated February 2, 2023, the Reporting Person was granted phantom shares on January 31, 2023 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. These phantom shares vest in equal installments on each of the first three anniversaries of the award.

Form 4 Insider Transactions: What Each Field Means →

02/03/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie H Erin

(Last)

(First)

(Middle)

50 HUDSON YARDS

(Street)

NEW YORK

10001

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BlackRock Health Sciences Trust [ BME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		Portfolio Manager

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/30/2026		M		11,449.5087	A	⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	11,449.5087	D
Common Stock	01/30/2026		D		11,449.5087	D	$41.87⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Shares	⁽¹⁾⁽⁵⁾	01/30/2026		A		6,379.1521		⁽¹⁾⁽⁵⁾	⁽¹⁾⁽⁵⁾	Common Stock	6,379.1521	$41.87	6,379.1521	D
Phantom Shares	⁽¹⁾⁽²⁾	01/30/2026		M			3,451.5026	⁽¹⁾⁽²⁾	⁽¹⁾⁽²⁾	Common Stock	3,451.5026	⁽¹⁾⁽²⁾	6,903.0052	D
Phantom Shares	⁽¹⁾⁽³⁾	01/30/2026		M			3,013.3991	⁽¹⁾⁽³⁾	⁽¹⁾⁽³⁾	Common Stock	3,013.3991	⁽¹⁾⁽³⁾	3,013.3991	D
Phantom Shares	⁽¹⁾⁽⁴⁾	01/30/2026		M			4,984.607	⁽¹⁾⁽⁴⁾	⁽¹⁾⁽⁴⁾	Common Stock	4,984.607	⁽¹⁾⁽⁴⁾	0.0000	D

Explanation of Responses:

1. A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash.

2. As previously reported on a Form 4 dated February 4, 2025, the Reporting Person was granted phantom shares on January 31, 2025 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date.

3. As previously reported on a Form 4 dated February 2, 2024, the Reporting Person was granted phantom shares on January 31, 2024 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date.

4. As previously reported on a Form 4 dated February 2, 2023, the Reporting Person was granted phantom shares on January 31, 2023 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date.

5. These phantom shares vest in equal installments on each of the first three anniversaries of the award.

	/s/ Gladys Chang as Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Erin H. Xie report for BlackRock Health Sciences Trust (BME)?

Erin H. Xie reported exercising derivative awards into 11,449.5087 common shares and selling the same number at $41.87 per share. The filing also shows new phantom share awards that are cash-settled and economically track BlackRock Health Sciences Trust common stock performance.

How many BlackRock Health Sciences Trust (BME) shares did the portfolio manager sell?

The portfolio manager sold 11,449.5087 shares of BlackRock Health Sciences Trust common stock. These shares were first acquired through an exercise coded “M” and then disposed of in a transaction coded “D” at a reported price of $41.87 per share on January 30, 2026.

Does Erin H. Xie still hold BlackRock Health Sciences Trust (BME) common stock after these transactions?

After the reported transactions, the Form 4 shows 0 shares of common stock beneficially owned directly. The filing indicates all 11,449.5087 shares acquired via derivative exercise were sold, while the remaining economic exposure is through phantom shares that are settled in cash, not stock.

How do the BlackRock Health Sciences Trust (BME) phantom shares for the insider vest and pay out?

The phantom shares vest in equal installments on each of the first three anniversaries of the award date. Once vested, they become payable in cash rather than stock, while remaining economically equivalent to one share of BlackRock Health Sciences Trust common stock per phantom share unit.